Toronto Dominion Bank Buys New Stake in Exagen Inc. (NASDAQ:XGN)

Toronto Dominion Bank acquired a new position in Exagen Inc. (NASDAQ:XGN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 891,366 shares of the company's stock, valued at approximately $3,655,000. Toronto Dominion Bank owned about 5.05% of Exagen at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in XGN. Corient Private Wealth LLC bought a new stake in Exagen during the fourth quarter valued at about $45,000. Virtu Financial LLC bought a new position in shares of Exagen during the 4th quarter worth approximately $46,000. Marshall Wace LLP purchased a new stake in Exagen during the fourth quarter valued at approximately $66,000. Northern Trust Corp boosted its stake in Exagen by 16.7% in the fourth quarter. Northern Trust Corp now owns 18,375 shares of the company's stock valued at $75,000 after acquiring an additional 2,630 shares in the last quarter. Finally, Palumbo Wealth Management LLC grew its holdings in Exagen by 13.5% in the fourth quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company's stock worth $355,000 after purchasing an additional 10,340 shares during the last quarter. Institutional investors own 75.25% of the company's stock.

Exagen Stock Performance

XGN stock traded down $0.02 during midday trading on Wednesday, reaching $7.37. The stock had a trading volume of 107,544 shares, compared to its average volume of 119,305. The firm has a fifty day simple moving average of $5.56 and a two-hundred day simple moving average of $4.57. Exagen Inc. has a 52-week low of $1.71 and a 52-week high of $7.56. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05. The stock has a market cap of $156.98 million, a PE ratio of -7.84 and a beta of 1.50.

Exagen (NASDAQ:XGN - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.20). Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. The business had revenue of $15.50 million for the quarter, compared to analyst estimates of $14.55 million. During the same period in the prior year, the company earned ($0.19) earnings per share. As a group, equities research analysts anticipate that Exagen Inc. will post -0.88 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on XGN shares. Canaccord Genuity Group increased their price objective on Exagen from $7.00 to $8.00 and gave the company a "buy" rating in a report on Tuesday, May 13th. William Blair reaffirmed an "outperform" rating on shares of Exagen in a research report on Wednesday, March 12th. Cantor Fitzgerald lowered their price target on Exagen from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Thursday, May 15th. BTIG Research restated a "buy" rating on shares of Exagen in a research note on Wednesday, May 7th. Finally, UBS Group restated an "overweight" rating on shares of Exagen in a report on Thursday, May 15th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $7.50.

Exagen Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).